This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Antibody-to-Assay Development
ELISA Development Services
Boster Bio has 30 years in ELISA manufacturing experience. We offer custom assay development for ELISA and Lateral Flow assays right here in the U.S.A. We can use commercial antibodies or start from designing and custom producing antibodies and standard proteins from scratch to build custom ELISA kits.
- Antibody + Assay Co-Development
- Native Matrix Performance Testing
- Epitope-Validated Pair Selection
- Lot-to-Lot Consistency Focus
Request a Quote
ELISA Powerhouse
2300+ ELISA kits developed through expert ELISA kit production
U.S.-Based Execution
San Diego-based assay development team
Antibody Library Access
Reagent sourcing and pairing
RUO and IVD Support
Regulatory-minded design
Manufacturing Readiness
Transfer and scale-up continuity
Common ELISA development issues
Design decisions that prevent technical risk downstream.
Epitope and Antigen Mismatch
Antibody pairs validated only against recombinant antigens fail when native samples present different folding or post-translational modifications. Boster Bio validates pairs against both recombinant and native target forms.
Matrix Interference and Background Noise
Assays optimized in buffer show high background or poor recovery in serum, plasma, or lysate. Real sample performance testing identifies and mitigates matrix effects early.
Reagent Lot Drift
Antibody or reagent lot changes cause assay drift. Manufacturing control over antibody production ensures batch-to-batch consistency and supply continuity.
Scale-Up and Transfer Failure
Assays developed without manufacturing constraints fail during scale-up or transfer. Boster Bio designs with plate coating uniformity, buffer stability, and SOP compatibility from the outset.
Development Process with Decision Checkpoints
Iterative, data-driven development with defined validation targets and go/no-go decision points at each phase.
-
Phase 1: Target Feasibility and Antibody Selection
Antigen characterization, epitope mapping, and antibody pair screening. Evaluate capture and detection candidates for compatibility and native target binding.
Decision Checkpoint: Select validated antibody pair or initiate custom antibody development. Confirm epitope accessibility in native samples.
-
Phase 2: Assay Architecture and Initial Optimization
Define sandwich or competitive format. Optimize coating concentrations, blocking conditions, and incubation parameters in buffer and target matrix.
Decision Checkpoint: Proceed if initial signal-to-noise meets target thresholds. Adjust architecture if interference or background exceeds limits.
-
Phase 3: Matrix Validation and Robustness Testing
Spike recovery, dilution linearity, and interference testing in real sample matrices. Assess cross-reactivity and selectivity against related analytes.
Decision Checkpoint: Confirm recovery within typical targets (customizable acceptance criteria) and minimal cross-reactivity. Iterate if matrix effects compromise accuracy.
-
Phase 4: Validation and Performance Qualification
Full analytical validation including precision, accuracy, sensitivity, range, and stability. Generate performance metrics aligned with intended use.
Decision Checkpoint: Final acceptance based on validation report meeting all defined criteria. Transfer readiness confirmed.
Supporting RUO and IVD Development Programs
U.S.-based assay development execution aligned with typical IVD documentation needs
Boster Bio's San Diego-based assay development team has supported both research use only (RUO) and in vitro diagnostic (IVD) development programs. Assays are designed with downstream manufacturing requirements in mind, including validation strategies, documentation practices, and quality control frameworks aligned with typical IVD development documentation needs.
U.S.-based execution ensures direct collaboration, iterative feedback, and design flexibility throughout development. Assays are built for transferability, scale-up, and long-term supply continuity.
Documentation Support
Assay development conducted with awareness of typical IVD development documentation needs. Documentation and traceability practices support programs aligned with regulatory pathway development.
Note: Boster Bio does not claim FDA approval or GMP certification. We are not clinically certified, and our services are intended to support customer programs requiring structured development practices. If you have any questions, please feel free to ask us.
Ready for ELISA assay development?
Leverage antibody manufacturing heritage and U.S.-based ELISA services and assay development execution. Request a quote or consult with our San Diego-based team.